← All market reports

Neurology & CNS Market Research Reports 2026

Neurology & CNS planning depends on how market access timing, pathway complexity, and institution-level execution interact across countries.

Neurodegeneration (Alzheimer anti‑amyloid infusions contentious but expanding where MRI safety monitoring infrastructures exist ), MS high efficacy BCD clones (natalizumab, ocrelizumab, ofatumumab self‑injectable shifts ), epilepsy adjunct small molecules versus cannabidiol special programs, migraine CGRP monoclonals revolutionizing episodic burden, plus movement disorder adjuncts modulate prescribing concentration within electrophys‑equipped neurologist panels. Stroke thrombolysis/thrombectomy capacity skews tertiary city clusters affecting secondary prevention antithrombotic and statin ramps.

Explore all market reports or compare market-level rollout constraints in the GCC country report hub. Current coverage includes GCC, Saudi Arabia, United Arab Emirates, Egypt, and 4 other markets.